Browsing Public Health by Subject "advanced breast cancer (ABC)' CDK4/6 cell cycle inhibitors' cyclin-dependent-kinase 4/6 inhibitors' effectiveness & efficiency (E&E)' HR+/HER-2 negative"
Now showing items 1-1 of 1
-
The effectiveness and safety of palbociclib and ribociclib in stage IV HR+/HER-2 negative breast cancer: a nationwide real world comparative retrospective cohort study
( Frontiers Media SA , 2023 , Article)Introduction: Palbociclib and ribociclib are indicated in the first-line treatment of hormonal receptor-positive HER-2 negative (HR+/HER2- negative) advanced breast cancer. Although randomized-controlled trials (RCTs) ...